Efficacy and safety of Compound danshen preparations combined with chemical drugs for peptic ulcer：a meta-analysis
- VernacularTitle:复方丹参制剂联合化学药治疗消化性溃疡有效性和安全性的Meta分析
- Author:
Yakun ZHAN
1
,
2
;
Jin ZENG
1
,
2
;
Ziwei HU
1
,
2
;
Juliang CHEN
1
Author Information
1. Dept. of Pharmacy，the Second Affiliated Hospital of Guangzhou University of Chinese Medicine，Guangzhou 510120，China
2. Dept. of Pharmacy，Zhuhai Hospital，Guangdong Provincial Hospital of Chinese Medicine，Guangdong Zhuhai 519000，China
- Publication Type:Journal Article
- Keywords:
compound danshen preparations;
peptic ulcer;
efficacy;
safety
- From:
China Pharmacy
2024;35(23):2915-2922
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To systematically evaluate the efficacy and safety of compound danshen preparations combined with conventional chemical drug treatment for peptic ulcer （PU）， providing evidence-based guidance for clinical treatment of PU. METHODS Related clinical randomized controlled trials were collected from CNKI， VIP， Wangfang data， CBM， PubMed， Embase and Web of Science from their establishment date to September 30， 2023. The qualities of included literature were evaluated by Cochrane Systematically Evaluator Manual 5.1.0. Meta-analysis， sensitivity analysis and publication bias analysis were conducted with RevMan 5.3 software. RESULTS Totally 26 pieces of literature were included with total of 2 451 cases， including 1 243 cases in trial group （compound danshen preparations+conventional chemical drug treatment） and 1 208 cases in the control group （conventional chemical drug treatment）. In terms of effectiveness， trial group had significant advantages in ulcer healing rate [OR＝4.66， 95%CI （3.53， 6.15）， P＜0.000 01]， HP eradication rate [OR＝1.90， 95%CI （1.12， 3.22）， P＝0.02]，and pain relief rate [OR＝3.91， 95%CI （2.31， 6.61）， P＜0.000 01] than control group， while ulcer recurrence rate [OR＝0.22， 95%CI （0.15， 0.32）， P＜0.000 01] and serum levels of pepsinogen （PG）Ⅰ [SMD＝－1.92， 95%CI （－2.25， －1.58）， P＜0.000 01]， PGⅡ [SMD＝－3.88， 95%CI （－4.35， －3.41）， P＜0.000 01] and G-17 [SMD＝－3.44， 95%CI （－3.87， －3.00）， P＜0.000 01] were significantly lower than control group. In terms of safety， the main adverse reactions were abdominal discomfort， headache， dizziness， dry mouth， facial flushing， etc. There was no significant difference in the incidence of adverse reactionsbetween the two groups [OR＝1.08， 95%CI （0.75， 1.54）， P＝0.69]. Subgroup analysis of ulcer healing rate and HP eradication rate based on dosage form showed that HP eradication rate in the compound danshen pellet group was not significantly improved compared to the control group， with consistent results for the remaining outcomes. The sensitivity analysis showed that above results were stable. There was less possibility of publication bias in this study. CONCLUSIONS Compared with conventional chemical drug treatment alone， the combination of compound danshen preparations can effectively improve the clinical symptoms of PU patients with similar safety.
